Recurrent high-grade gliomas pose a treatment challenge; this study evaluates the effectiveness and tolerability of Hypofractionated Stereotactic Radiation (HFSRT) in re-irradiation.
A retrospective analysis of 52 patients treated between 2011 and 2021 showed median overall survival of 12 months, with re-irradiation doses differing among patients.
The treatment was mostly well-tolerated, with minimal severe side effects, indicating HFSRT as a promising option for managing these tumors.